Iovance Biotherapeutics Inc. buy The Goldman Sachs Group, Inc.
Start price
03.03.25
/
50%
€3.90
Target price
03.03.26
€18.11
Performance (%)
-38.56%
Price
23.12.25
€2.40
Summary
This prediction is currently active. The BUY prediction by The_Goldman_Sachs_Gr for Iovance Biotherapeutics Inc. is performing very badly with a performance of -38.56%. This prediction currently runs until 03.03.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Iovance Biotherapeutics Inc. | 13.340% | 13.340% |
| iShares Core DAX® | 0.224% | 2.031% |
| iShares Nasdaq 100 | 0.371% | -0.955% |
| iShares Nikkei 225® | 0.972% | -0.953% |
| iShares S&P 500 | 0.417% | -0.622% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Iovance Biotherapeutics Inc. diskutieren
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $22.00 to $19.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Stopped prediction by The_Goldman_Sachs_Gr for Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€1.60
15.07.25
15.07.25
€0.86
15.07.26
15.07.26
49.82%
23.12.25
23.12.25
Iovance Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€1.71
12.05.25
12.05.25
€7.13
12.05.26
12.05.26
40.04%
23.12.25
23.12.25
Iovance Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€2.71
17.04.25
17.04.25
€14.08
17.04.26
17.04.26
-11.57%
23.12.25
23.12.25
Iovance Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€14.52
29.02.24
29.02.24
€19.38
28.02.25
28.02.25
-72.27%
01.03.25
01.03.25
Iovance Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€11.80
20.02.24
20.02.24
€17.55
20.02.25
20.02.25
-53.22%
21.02.25
21.02.25
Iovance Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€5.05
20.11.23
20.11.23
€10.98
20.11.24
20.11.24
53.15%
21.11.24
21.11.24

